PLSE

PLSE

USD

Pulse Biosciences Inc Common Stock (DE)

$16.060-0.440 (-2.667%)

Prix en Temps Réel

Healthcare
Medical Instruments & Supplies
États-Unis

Graphique des Prix

Loading Chart...

Métriques Clés

Métriques de Marché
Fondamentaux de l'Entreprise
Statistiques de Trading

Métriques de Marché

Ouverture

$16.500

Haut

$16.770

Bas

$15.800

Volume

0.11M

Fondamentaux de l'Entreprise

Capitalisation Boursière

1.1B

Industrie

Medical Instruments & Supplies

Pays

United States

Statistiques de Trading

Volume Moyen

0.18M

Bourse

NCM

Devise

USD

Intervalle sur 52 Semaines

Bas $13.766Actuel $16.060Haut $25

Actualités Connexes

BusinessWire

Pulse Biosciences Announces First Enrollment in the NANOCLAMP AF Study

First U.S. Surgical Treatments with PFA Clamp for Patients with Atrial Fibrillation During Concomitant Surgical Procedure Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel nPulse™ technology

Voir plus
Pulse Biosciences Announces First Enrollment in the NANOCLAMP AF Study
BusinessWire

Pulse Biosciences Schedules Third Quarter 2025 Business Updates and Financial Results Conference Call for November 5, 2025

Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced it

Voir plus
Pulse Biosciences Schedules Third Quarter 2025 Business Updates and Financial Results Conference Call for November 5, 2025
BusinessWire

Pulse Biosciences Announces Presentation of Late-Breaking Data From the nPulse™ Cardiac Surgical System First-in-Human Feasibility Study at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting

Successfully treated atrial fibrillation (AF) in initial 30 patients with the nPulse™ Cardiac Surgical System Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel nPulse™ technology

Voir plus
Pulse Biosciences Announces Presentation of Late-Breaking Data From the nPulse™ Cardiac Surgical System First-in-Human Feasibility Study at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting
BusinessWire

Pulse Biosciences Announces Clinical Data Highlighting its nPulse™ Cardiac Surgical System to be Presented at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting

Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced

Voir plus
Pulse Biosciences Announces Clinical Data Highlighting its nPulse™ Cardiac Surgical System to be Presented at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting

Restez Informé

Configurez des alertes de prix, recevez des mises à jour d'analyses IA et des actualités de marché en temps réel.